Sari, IsmailPinarbasi, HaticePinarbasi, ErgunYildiz, Caglar2019-07-272019-07-282019-07-272019-07-2820171064-19551525-6065https://dx.doi.org/10.1080/10641955.2017.1388390https://hdl.handle.net/20.500.12418/6942Objective: In this study the association between K55R polymorphism, methylation level of the EPHX2 promoter region, and PE was investigated in 520 individuals including 260 PE patients and 260 healthy pregnant women.Methods: K55R polymorphism and methylation level of the EPHX2 promoter were determined by the real-time PCR using double-dye hydrolysis probes and methylation-sensitive high-resolution melting analysis, respectively.Results: The presence of the K55R polymorphism was significantly higher in cases (28.1%) than controls (17.3%), and was associated with increased risk of PE (OR: 1.86; 95% CI: 1.09-2.63). Methylation levels of the EPHX2 promoter region in cases were significantly lower than controls. A 2.83 times increased PE risk was observed in pregnant women with EPHX2 promoter methylation levels of <25% (OR: 2.83; 95% CI: 1.15-6.91).Conclusion: In conclusion, hypomethylation of the promoter region of EPHX2 and K55R polymorphism were associated with significant increased risk of PE. sEH enzyme may play a role in the pathogenesis of PE by contributing to reduction of the vasodilatator, anti-hypertensive, and anti-inflammatory effects of EETs by rapid degradation of these molecules.en10.1080/10641955.2017.1388390info:eu-repo/semantics/closedAccessSoluble epoxide hydrolasegenetic polymorphismepoxyeicosatrienoic acidmethylationArticle364325315290584922-s2.0-85031933699Q2WOS:000418577600006Q4